Market Cap (In USD)
4262.00
Revenue (In USD)
-
Net Income (In USD)
-
Avg. Volume
778.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-5-0.25
- PE
- -
- EPS
- -
- Beta Value
- 37.044
- ISIN
- US4833471000
- CUSIP
- 483347100
- CIK
- 1751299
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Kimberly Hocknell
- Employee Count
- -
- Website
- https://kaleido.com
- Ipo Date
- 2019-02-28
- Details
- Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
More Stocks
-
WQNIWQN, Inc.
WQNI
-
RPC
-
PNTRFPantera Silver Corp.
PNTRF
-
DOCKF
-
MSBNMessaben Corp.
MSBN
-
601158
-
PLAZ-LPlaza Centers N.V.
PLAZ-L
-
7030